UCI Health Chao Family Comprehensive Cancer Center | Strategic Alliance Partners

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Catherine C. Coombs, MD, presents data investigating venetoclax-based therapy after Bruton tyrosine kinase inhibitors in chronic lymphocytic leukemia.

A novel approach to chemotherapy administration in advanced gastric cancer that has progressed to gastric carcinomatosis is poised to alter the treatment landscape and improve outcomes for this patient population.

Pembrolizumab plus chemotherapy with or without bevacizumab prolonged progression-free survival and overall survival in key subgroups of patients with persistent, recurrent, or metastatic cervical cancer, displaying benefits similar to those seen in the broader patient population.

The majority of patients with newly diagnosed chronic lymphocytic leukemia have better outcomes with BTK inhibitors compared with standard chemoimmunotherapy, making them the logical choice for frontline therapy.

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses the FDA approval of pembrolizumab (Keytruda) in small cell lung cancer (SCLC).

Sai-Hong I. Ou, MD, PhD, professor, Division of Hematology/Oncology, Department of Medicine, University of California Irvine School of Medicine, discusses investigational KRAS inhibitors in lung cancer.

Sai-Hong I. Ou, MD, PhD, discusses the status of different mutations in lung cancer and the work being done to bring clinically meaningful treatments to the space.

Sai-Hong I. Ou, MD, highlights the conveniences of liquid biopsies relative to tissue biopsies, as well as current drawbacks to their use in detecting targetable alterations in lung cancer.

The frontline combination of fulvestrant and anastrozole resulted in a sustained benefit in progression-free survival and a significant improvement in overall survival compared with anastrozole alone in patients with postmenopausal, HR–positive metastatic breast cancer, according to long-term results of the SWOG S0226 trial.

Susan M. O'Brien, MD, discusses some of the latest intriguing data in the treatment of chronic lymphocytic leukemia and what this means for physicians and patients.

Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).

It was little more than 3 years ago that ibrutinib became the first Bruton tyrosine kinase (BTK) inhibitor to gain the FDA’s approval with a second-line indication for patients with mantle cell lymphoma.

Susan M. O'Brien, MD, associate director for Clinical Science for the Chao Family Comprehensive Cancer Center, medical director of the Sue and Ralph Stern Center for Cancer Clinical Trials and Research, UC Irvine Health, discusses how ibrutinib (Imbruvica) compares with chemoimmunotherapy as a frontline treatment for patients with chronic lymphocytic leukemia.

Susan M. O'Brien, MD, discusses upcoming novel treatments in relapsed/refractory chronic lymphocytic leukemia, such as the next generation of inhibition with BTK, SYK, and PI3K, as well as the outcomes of the recent RESONATE-2 trial.

Susan M. O'Brien, MD, discusses the impact and the future outlook for idelalisib and ibrutinib in chronic lymphocytic leukemia.

Sai-Hong Ignatius Ou, MD, PhD, Health Science Associate Clinical Professor, University of California, Irvine, Chao Family Comprehensive Cancer Center, University of California Irvine Medical Center, Orange, California, discusses data on alectinib as treatment for patients with non-small cell lung cancer (NSCLC) with brain metastases.